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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is characterized by 
multivariate systemic complications that significantly 
impair the quality of life of patients and reduce their life 
expectancy [1]. 
T2DM is considered an absolute risk factor for athero-
sclerosis [2]. The basis of this pathological process is a 
violation of carbohydrate metabolism, one of its mani-
festations is hyperglycemia, which leads to changes in the 
lipid spectrum of blood (deviate from normal levels of total 
cholesterol, triglycerides, high and low-density lipopro-
tein cholesterol) [3]. In the long run, lipid-protein glycan 
complexes are deposited in blood vessels, leading to the 
development of diabetic micro- or macroangiopathy [3, 4].
Therefore, chronic microvascular complications of T2DM 
include nephropathy, erectile dysfunction, cataracts, and 
retinopathy, the consequences of which are blindness, neu-
ropathy with a distant complication – amputation of limbs 
and others [5]. Instead, chronic macrovascular complica-
tions of T2DM include atherosclerotic lesions of the lower 
extremities resulting in the diabetic foot, which in turn may 
be complicated by the need for amputation of limbs, stroke, 
coronary heart disease (CHD) with a possible course: angina 
and/or myocardial infarction (MI) and others [6].
According to studies, patients with T2DM are overweight 
and obese [7]. Obesity from a pathophysiological point of 
view is considered as a chronic inflammatory process that 
has a complex and detrimental effect on the whole body 
in general, provoking the development of hypertension, 
impaired glucose metabolism, vascular damage (accelera-
tion of atherosclerosis and its consequences), contributing 
to the development of cardiovascular complications (MI, 
stroke, etc.), infertility, oncology, obstructive sleep apnea 
syndrome, etc. [7, 8]. Several clinical studies have shown 
that anthropometric parameters are closely related to the 
risk of cardiovascular disease (CVD): body mass index 
(BMI), waist circumference (WC), hip circumference 
(HC), and waist-to-hip ratio (WHR) [9]. Each additional 
kilogram of weight directly affects the final value of blood 
pressure, while the increase in waist WC, HC, WHR is 
closely related to the predictor of CVD [10]. That is why 
obesity is considered an additional factor of cardiovascular 
risk (CVR).
Quite often there is a comorbid combination of T2DM 
and hypertension, which significantly accelerates the patho-
logical process of vascular endothelial damage, both meta-
bolic pathogenesis and changes in vascular pressure, which 
exacerbates the development of vascular complications of 
the kidneys and heart, brain, peripheral vessels of the lower 
extremities [11]. Thus, the risk of CHD, stroke and dozens of 
times, vision loss, amputation of the lower extremities, and 
other complications increases several times [11].
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ABSTRACT
The aim: To analyze and calculate CVR in patients with T2DM and concomitant obesity.
Materials and methods: The selection of patients was carried out based on the Uzhhorod District Clinical Hospital, in the period from November 2016 to January 2020. All 
patients were divided into 3 groups: 1 (n=93) with T2DM and concomitant obesity, 2 (n=87) with T2DM, 3 (n=39) with obesity. The treatment period lasted 1 year and included 
dosed exercise for at least 30 minutes per day and dietary recommendations. Patients in groups 1 and 2 received metformin 850 mg twice daily in combination with dapagliflozin 
10 mg once daily. CVR was determined at the time of enrollment and after 1 year of treatment using: American College of Cardiology / American Heart Association Guideline on 
the Assessment of Cardiovascular Risk (2013) (ASCVD Risk) and Framingham Risk Score (FRS).
Results: The data obtained as a result of the study revealed the highest CVR in patients of group 1, in contrast to group 2 and 3 (p<0.05). After 1 year of complex treatment, 
CVR indicators were statistically significantly reduced in all experimental groups (p<0.05).
Conclusions: Determining CVR parameters and exposure to them within 10 years can remove unwanted cardiovascular complications.
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Cardiovascular complications as a consequence of 
T2DM can be prevented and in some cases removed by 
determining the patient’s CVR, know the prognosis for 
the patient and make a comprehensive correction based 
on individual needs.
From a practical point of view, various methods of as-
sessing CVR are widely used, in particular in the 10-year 
perspective: Q risk 2 score calculator and Modified Q risk 
2, PROCAM score, The Framingham risk score (FRS), 
SCORE, American College of Cardiology / American Heart 
Association Guideline on the Assessment of Cardiovascu-
lar Risk (2013) (ASCVD Risk) [12-16].
SCORE, FRS, ASCVD Risk remain the most widely 
used in routine clinical practice to assess CVR. Thus, the 
SCORE scale, created based on the results of clinical trials 
involving more than 250,000 patients, allows us to assess 
the risk of fatal cardiovascular events (CVE) in the next 
10 years. [13, 15, 16]. 
American College of Cardiology / American Heart As-
sociation Guideline on the Assessment of Cardiovascular 
Risk (2013) (ASCVD Risk) is categorized as low-risk 
(<5%), borderline risk (5% to 7.4%), intermediate-risk 
(7.5% to 19.9%), high risk (≥20%) of 10-year risk of MI 
and/or stroke [15, 17].
The Framingham Risk Score (FRS) for hard CHD which 
evaluates the ten-year risk of CVD (CHD, stroke, chronic 
heart failure, heart death) in percentage was calculated by 
total points was classified as low risk (<10%), intermedi-
ate-risk (10–20%), and high risk (>20%) [14, 18].
CVD is one of the leading causes of global mortality and 
one of the most common causes of disability. CVD prev-
alence increased from 271 million in 1990 to 523 million 
in 2019 and continues to rise, while the number of CVD 
deaths increased from 12.1 million in 1990 to 18.6 million 
in 2019 [19]. 
Annually increasing costs associated with CVD, par-
ticularly so in the USA alone as of 2015 spent 126 billion 
dollars and are projected to grow more than 2.5 times to 
309 billion dollars in 2035 [20]. 
THE AIM 
Analyze and calculate CVR in patients with T2DM and 
concomitant obesity and comprehensively influence the 
obtained CVR, reducing the 10-year risk of CVE.
MATERIALS AND METHODS
The selection of patients took place based on the thera-
peutic department of the Municipal Non-Profit Enterprise 
“Uzhhorod District Clinical Hospital of Uzhhorod District 
Council of Transcarpathian region”, and at outpatient treat-
ment department of the therapy and the family medicine of 
the Faculty of Postgraduate and Pre-University Education 
of the State Higher Educational Establishment «Uzhhorod 
National University» in the period from November 2016 
to January 2020. In the course of the study, 93 people with 
T2DM and concomitant obesity, who were included in 
the 1st group, were examined and 126 medical cards of 
an inpatient with a diagnosis of T2DM and ambulatory 
card data included in the 2nd group were retrospectively 
analyzed. group (n=87), while group 3 included patients 
diagnosed with obesity (n=39). The treatment period in 
patients lasted 1 year and included dosed exercise lasting 
at least 30 minutes a day and dietary recommendations, 
also patients in groups 1 and 2 received metformin 850 
mg 2 times a day in combination with dapagliflozin 10 
mg 1 time per day. 
All subjects were examined: general clinical examination, 
anthropometric measurements, calculation of BMI, WC, 
HC, WHR, glycosylated hemoglobin (HbA1c), lipid profile, 
collection of medical and social history, and bad habits. All 
patients in the study were additionally interviewed about 
the correctness of dietary and treatment recommendations.
CVR was determined at the time of inclusion in the study 
and after 1 year of treatment. The following calculators 
were used to calculate the CVR: 1) American College of 
Cardiology/American Heart Association Guideline on 
the Assessment of Cardiovascular Risk (2013) (ASCVD 
Risk) is categorized as low-risk (<5%), borderline risk 
(5% to 7.4%), Intermediate risk (7.5% to 19.9%), high risk 
(≥20%) of 10-year risk of MI and/or stroke [15, 17] and 2) 
The Framingham Risk Score (FRS) for hard CHD which 
evaluates the ten-year risk of CVD (CHD, stroke, chronic 
heart failure, heart death) in percentage was calculated by 
total points was classified as low risk (<10%), intermedi-
ate-risk (10–20%), and high risk (>20%) [14, 18].
Additionally, to find the potential risk for patients with 
T2DM, a bibliographic search was performed on the 
keywords “treatment of type 2 diabetes mellitus”, “type 
2 diabetes mellitus”, “dapagliflozin”, “metformin”, “risk 
factors”, “cardiovascular risk” in the following databases 
PubMed, MEDLINE, Web of Science, Cochrane Library, 
Google Akademy.
The diagnosis criteria for T2DM were established based 
on the American Diabetes Association. The diagnosis of 
obesity was established by measuring BMI≥30 kg/m2, and 
the value of BMI was assessed by the degree of obesity.
The statistical processing of the research results was per-
formed using the program software International Business 
Machines Corporation Statistical Package for the Social 
Sciences Statistics. The statistical analysis of the materials, 
the summary, and also the summary of the conclusions 
were made by the method of the variation statistics, taking 
into account the average values (mod, median, arithmetic 
mean) and the average error (M±m), with the estimation 
of the reliability of the values by the Student’s t-criterion, as 
well as with the determination of the correlation coefficient 
using the  Pearson’s paired method to identify the relation-
ships between the obtained indicators. For the minimum 
threshold of probability, the values p<0.05 were taken.
The whole set of the surveys were by the Articles 3,44 of the 
Fundamentals of the Legislation of Ukraine on Healthcare, 
the Articles 7, 8 of the Law of Ukraine “On Medicines”, the 
Law of Ukraine “On Protection of Personal Data”, taking into 
account the requirements of the European Parliament and 
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Council Directives 2001/20/ EU of April 4, 2001, 2001/83/ 
EU of  November 6, 2001, the Decisions of the European Par-
liament and of the Council 1901/2006 of December 12, 2006, 
and 1902/2006 of December 20, 2006, ICH GCP, International 
Ethical Principles for Biomedical human-related research and 
physician code of conduct, and order in the Ministry of Health 
of Ukraine No. 690 of September 23, 2009, as well as the order 
of the Ministry of Health of Ukraine No. 1118 of December 
21, 2012, the unified clinical protocol of the primary and the 
secondary (specialized) medical care of T2DM.
RESULTS
Those included in this study were ≥40 years old. The mean 
age of the patients in the 1st group was 51.3±1.2 years, 
compared with 52.7±1.1 years of the patients in the 2nd 
group, whereas in group 3 the age of patients was 54.5±1.2 
years. The ratio of men and women in group 1 was 32 men 
and 61 women against 34 men and 53 women in group 2 
and 18 men and 21 women in group 3. The mean duration 
of T2DM in group 1 was 14.8±3.2 years, as opposed to 
13.5±1.6 years in group 2.
Currently, the status of a smoker was in group 1 – 29 
people, group 2 – 17 people, and group 3 – 22 people. 
Instead, in the past, there were additionally smokers in 
group 1 – 13 people, in group 2 – 8 people, and group 3 – 6 
people. Hypertensive disease and received treatment for it: 
in group 1 – 35 people, in group 2 – 21 people, and group 
3 – 27 people. MI was suffered in the past: in group 1 – 11 
people, in group 2 – 7 people, and group 3 – 4 people. 
Instead, during 1 year of observation, MI was additionally 
transferred: in group 1 – 3 persons, in group 2 – 1 person, 
and group 3 – 2 persons. Stroke was suffered in the past: in 
group 1 – 8 people, in group 2 – 3 people, and group 3 – 1 
person. Instead, during 1 year of follow-up, an additional 
stroke: in group 1 – 2 people, in group 2 – 3 people, and 
in group 3 – 2 people. Aspirin therapy was taken: in group 
1 – 36 people, in group 2 – 15 people, and group 3 – 11 
people. Statins were taken: in group 1 – 24 people, in group 
2 – 11 people, and in group 3 – 7 people.
At the beginning of the study, according to the obtained 
data on BMI: in group 1 – 58 people were with grade I 
obesity, 23 people had grade II obesity, 11 people had grade 
III obesity; in group II – 53 people were overweight, while 
34 people were normal weight; in group 3 – 25 people were 
with I degree of obesity, 11 people had II degree of obesity 
and 3 people with obesity of III degree.
According to the data obtained as a result of the measur-
ing anthropometric parameters of the patients of the 1st 
and the 2nd group and 1st and the 3rd group at the begin-
ning of the study, no statistically significant difference was 
found between them (p>0.05). The BMI at the beginning 
of the study in group 1 was 32,57±0,18 kg/m2, respectively 
28,74±0,21 kg/m2 in group 2 and 32,24±0,32 kg/m2 in 
group 3. The WC index in group 1 at the beginning of the 
study was 110,59±1,35 cm, respectively 88,41±1,17 cm 
in group 2, and 108,62±1,19 cm in group 3. WHR in the 
group 1 was 1,07±0,01 and 0,95±0,01, respectively in the 
group 2 and 1,03±0,01 cm in the group 3.
It is noteworthy that 12 months after the course of com-
prehensive treatment and observation, between anthro-
pometric indicators of patients of the 1st and 2nd group 
there was a statistically significant difference, the same 
dynamics were also observed when comparing the 1st and 
3rd groups (p<0.05).
If at the beginning of the study in group 1 HbA1C was 
8.3±0.05%, then after 12 months of complex treatment 
and observation 7.51±0.03%, against the response of 
8.12±0.08% and 6.45±0.04%, respectively, in the second 
group. In contrast, in patients of group 3 before and after 12 
months of complex treatment and observation, indicators 
within the norm of HbA1C were observed – 5.77±0.06% 
and 5.49±0.03%, respectively. According to the obtained 
laboratory data of FPG and HbA1C, in patients of the 1st 
and 2nd groups and the 1st and 3rd groups at the begin-









BMI B (kg/m2) 32,57±0,18 28,74±0,21 32,24±0,32
WC B (cm) 110,59±1,35 88,41±1,17 108,62±1,19
HC B (cm) 103,8±0,92 92,6±1,04 105,17±0,89
WHR B 1,07±0,01 0,95±0,01 1,03±0,01
BMI AT (kg/m2) 31,34±0,22 27,32±0,17* 30,67±0,26#
WC AT (cm) 104,67±1,18 85,72±1,12* 103,70±1,08#
HC AT (cm) 101,2±1,04 90,3±1,19* 102,21±0,89#
WHR AT 1,03±0,01 0,95±0,01* 1,01±0,01#
Note: B - patient data at the beginning of the study; AT - patient data 
after 12 months of treatment and follow-up; BMI - Body Mass Index; 
WC - Waist circumference; HC - the hip circumference; WHR - waist-to-hip 
ratio; * - statistically significant difference when comparing the indicators 
between the respective groups 1 and 2 (p<0.05); # - a statistically signif-
icant difference when comparing the indicators between the respective 
groups 1 and 3 (p<0.05).









FPG B 9,21±0,17 8,96±0,11 5,81±0,12
HbA1C (%) B 8,3±0,05 8,12±0,08 5,77±0,06
FPG AT 7,21±0,08 6,69±0,12* 5,51±0,15#
HbA1C (%) AT 7,51±0,03 6,45±0,04* 5,49±0,03 #
Note: B - patient data at the beginning of the study; AT - patient data after 
12 months of treatment and follow-up; FPG – Fasting plasma glucose; 
HbA1C – glycated hemoglobin; normal values of FPG – 3.3-5.5 mmol/l; 
normal values of HbA1C – 4-6.4%; * - statistically significant difference 
when comparing the indicators between the respective groups 1 and 2 
(p<0.05); # - a statistically significant difference when comparing the 
indicators between the respective groups 1 and 3 (p<0.05).
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ning of the study, no statistically significant difference was 
found between them (p>0.05). Analyzing the biochemical 
parameters of the blood, namely the metabolism of hydro-
carbons, there is a tendency to reduce the level of fasting 
plasma glucose (FPG) and HbA1C in groups 1 and 2. There 
was a statistically significant difference between FPG and 
HbA1C in patients of groups 1 and 2 and groups 1 and 3 
after 12 months of study (p<0.05).
In all study groups, at the beginning of the study, there was 
an increased level of triglycerides, a decrease in high-density 
lipoprotein, and an increase in low-density lipoprotein. The 
level of triglycerides slightly decreased after treatment, com-
pared with a baseline before treatment, but was still extremely 
high, a statistically significant difference between patients 1 
and 2 groups and between patients 1 and 3 groups was not 
observed (p>0.05). In groups 1 and 2 at the beginning of the 
study, there was an increase in the concentration of apolipo-
protein B over 120 mg/dl, while in groups 3 this figure was 
within normal limits. Targets of the lipid profile in the experi-
mental groups after the course of treatment were not achieved.
The other biochemical parameters obtained at different stages 
of the study did not reveal the statistically significant changes 
in the indicators of the groups 1 and 2 and 1 and 3 (p>0.05).
At the beginning of treatment, ASCVD Risk in patients 
of group 1 was 12.7±0.1%, group 2 – 11.8±0.2%, and 
group 3 6.8±0.2%, respectively. At the end of treatment, 
ASCVD Risk in patients of group 1 was 9.5±0.1%, group 
2 – 9.2±0.3%, and group 3, respectively, 6.4±0.2%. There 
was a statistically significant difference between ASCVD 
Risk, between patients in groups 1 and 2 and groups 1 and 
3 after 12 months of study (p<0.05).
At the beginning of treatment, FRS in patients of 
group 1 was 24.6±0.4%, group 2 – 18.5±0.3%, and group 
3 14.8±0.5%, respectively. At the end of FRS treatment 
in patients of the 1st group 21.5±0.4%, the 2nd group – 
16.1±0.4%, and the 3rd group 12.3±0.2%, respectively.
Thus, after a comprehensive examination with the 
identification of risk factors for cardiovascular events and 
subsequent calculation of CVR, after a course of treatment, 
there was a tendency to decrease this indicator. However, 
in 12 months of treatment and follow-up, new episodes 
of CVE were recorded, which unfortunately could not be 
prevented. Therefore, patients of all study groups were 
provided with further treatment recommendations and 
advice on continuing lifestyle modifications followed by 
follow-up.
DISCUSSION
 Even though many medical instruments help to individ-
ually assess the CVR in a 10-year period, covering several 
clinical and laboratory data of the patient, they remain 
quite rough instruments [16-18]. However, CVR scales 
do not include other equally important RF that may di-
rectly affect the CVE prognosis over a 10-year period [19]. 
Treatment recommendations are based on data from the 
CVR, are group character that can reduce the effectiveness 
of individual therapy. 
Therefore, more individualized scales for assessing CVR 
are currently being developed. Future CVR scales on the 
way to personalized medicine may take into account 
individual genetic characteristics, which will significant-
ly increase their sensitivity. New and individual CVR 
assessment scales may lead to a rethinking of treatment 
guidelines and significantly improve treatment outcomes.
CONCLUSIONS
Patients with T2DM and concomitant obesity have 
higher CVR rates compared with groups of patients with 
T2DM and obesity alone. It is also important that in the 
long run, in 10 years or more, the indicators of CVR can 
be corrected, which reduces the risk of the patient having 
unwanted CVE and potential disability of the patient.
The frequency of CVE can be reduced by providing 
patients with adequate comprehensive treatment and 
control of blood pressure and hydrocarbon metabolism, 
lifestyle modifications, and the like. However, new car-
diovascular events may occur due to unmodified risk 
factors and/or insufficient exposure to modified risk 
factors.
Table III. Assessment of CVR on the American College of Cardiology/
American Heart Association Guideline on the Assessment of Cardiovascular 









ASCVD Risk (%) B 12,7±0,1 11,8±0,2 6,8±0,2
ASCVD Risk (%) AT 9,5±0,1 9,2±0,3* 6,4±0,2#
Note: B - patient data at the beginning of the study; AT - patient data after 
12 months of treatment and follow-up; CVR – cardiovascular risk; ASCVD 
Risk - assessment of cardiovascular risk; ASCVD Risk is categorized as 
low-risk (<5%), borderline risk (5% to 7.4%), intermediate-risk (7.5% to 
19.9%), high risk (≥20%) of 10-year risk of myocardial infarction and/or 
stroke; * - statistically significant difference when comparing the indicators 
between the respective groups 1 and 2 (p<0.05); # - a statistically signif-
icant difference when comparing the indicators between the respective 
groups 1 and 3 (p<0.05).









FRS (%) B 24,6±0,4 18,5±0,3 14,8±0,5
FRS (%) AT 21,5±0,4 16,1±0,4* 12,3±0,2#
Note: B - patient data at the beginning of the study; AT - patient data after 12 
months of treatment and follow-up; FRS - Framingham Risk Score; FRS was 
classified as low risk (<10%), intermediate-risk (10–20%), and high risk 
(>20%) of ten-year risk cardiovascular disease; * - statistically significant 
difference when comparing the indicators between the respective groups 
1 and 2 (p<0.05); # - a statistically significant difference when comparing 
the indicators between the respective groups 1 and 3 (p<0.05). 
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